Michael Shetzline M.D., Ph.D.
Net Worth

Last updated:

What is Michael Shetzline M.D., Ph.D. net worth?

The estimated net worth of Dr. Michael Shetzline M.D., Ph.D. is at least $5,109,279 as of 20 May 2024. He owns shares worth $454,677 as insider, has earned $1,573,482 from insider trading and has received compensation worth at least $3,081,120 in Ironwood Pharmaceuticals, Inc..

What is the salary of Michael Shetzline M.D., Ph.D.?

Dr. Michael Shetzline M.D., Ph.D. salary is $770,280 per year as Chief Medical Officer, Senior Vice President and Head of R&D in Ironwood Pharmaceuticals, Inc..

How old is Michael Shetzline M.D., Ph.D.?

Dr. Michael Shetzline M.D., Ph.D. is 66 years old, born in 1959.

What stocks does Michael Shetzline M.D., Ph.D. currently own?

As insider, Dr. Michael Shetzline M.D., Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Ironwood Pharmaceuticals, Inc. (IRWD) Chief Medical Officer, Senior Vice President and Head of R&D 413,719 $1.1 $454,677

What does Ironwood Pharmaceuticals, Inc. do?

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

IRWD logo
IRWD
Ironwood Pharmaceuticals, Inc.
$1.1

Michael Shetzline M.D., Ph.D. insider trading

Ironwood Pharmaceuticals, Inc.

Dr. Michael Shetzline M.D., Ph.D. has made 18 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 16,128 units of IRWD stock worth $104,026 on 20 May 2024.

The largest trade he's ever made was exercising 38,618 units of IRWD stock on 12 Feb 2024. As of 20 May 2024 he still owns at least 413,719 units of IRWD stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Class A Common Stock 16,128 $6.45 $104,026
Option
Class A Common Stock 34,936 N/A N/A
Option
Performance-based Restricted Stock Unit 34,936 N/A N/A
Sale
Class A Common Stock 38,618 $15.24 $588,538
Sale
Class A Common Stock 10,324 $10.12 $104,479
Sale
Class A Common Stock 2,416 $11.31 $27,325
Sale
Class A Common Stock 7,438 $11.31 $84,124
Sale
Class A Common Stock 2,322 $11.41 $26,494
Sale
Class A Common Stock 7,146 $11.41 $81,536
Sale
Class A Common Stock 7,453 $11.5 $85,710
Sale
Class A Common Stock 3,130 $11.5 $35,995
Sale
Class A Common Stock 4,364 $10.77 $47,000
Sale
Class A Common Stock 3,804 $10.77 $40,969
Sale
Class A Common Stock 5,161 $10.77 $55,584
Sale
Class A Common Stock 2,911 $10.77 $31,351
Sale
Class A Common Stock 1,367 $10.77 $14,723
Sale
Class A Common Stock 13,776 $11.58 $159,526
Sale
Class A Common Stock 2,077 $12.25 $25,443
Sale
Class A Common Stock 4,439 $4.56 $20,220
Sale
Class A Common Stock 4,439 $9.11 $40,439

Ironwood Pharmaceuticals key executives

Ironwood Pharmaceuticals, Inc. executives and other stock owners filed with the SEC: